Search results
Integer (NYSE:ITGR) Stock Rating Reaffirmed by Benchmark
ETF DAILY NEWS· 12 hours agoBenchmark reissued their buy rating on shares of Integer (NYSE:ITGR – Free Report) in a report issued on Friday morning, Benzinga reports. They currently have a $130.00 target price on the & ...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 1 day agoSecond System to be Utilized by one of the Largest Private Hospital Systems in Japan RESEARCH...
AFib: AI detects irregular heartbeat 30 minutes before it occurs
Medical News Today· 20 hours agoAbout 59 million people globally had atrial fibrillation (AFib) in 2019. AFib is not usually life...
Don't just track your steps: 4 health points to monitor on your smartwatch
WLTX-TV Columbia· 4 days ago"There's lots of different metrics now that we can begin to look at," says Dr. Davin Lundquist,...
Seniors, These Products and Services Could Improve Your Life
Cheapism via AOL· 1 day agoFrom safety products like bed rails to electronic devices like big-button TV remotes, minor...
Analysis | Whatever happened to Biden’s public option?
Washington Post· 4 days agoAs we ramp up for the 2024 election, I’ve wondered why talk of the public option has disappeared....
Fortrea (FTRE) to Release Earnings on Tuesday
ETF DAILY NEWS· 11 hours agoAnalysts expect the company to announce earnings of ($0.01) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.
InspireMD (NYSE:NSPR) Coverage Initiated at StockNews.com
ETF DAILY NEWS· 5 days agoEquities research analysts at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR – Get Free Report) in a research report issued on Wednesday. The brokerage set a “sell” rating ...
Psychedelic Tx: What Meaningful Informed Consent Looks Like
Medscape· 12 hours agoA psychedelic renaissance is underway in psychiatric medicine, with a growing number of studies...
Tandem Diabetes Care (NASDAQ:TNDM) PT Raised to $40.00 at Stifel Nicolaus
ETF DAILY NEWS· 6 days agoThe firm presently has a “buy” rating on the medical device company’s stock. Stifel Nicolaus’ price target would indicate a potential upside of 13.90% from ...
